APPENDIX V

STATUTORY AND GENERAL INFORMATION

On January 6, 2017, our Shareholders resolved to increase the registered capital of our
Company from RMB550,000,000 to RMB584,750,000 by issuing 34,750,000 new Shares to
four investors at an aggregate consideration of RMB319,700,000. The registration of such
increase of registered capital with the Administration for Industry and Commerce was
completed on July 5, 2017.

On February 23, 2018, our Shareholders resolved to increase the registered capital of our
Company from RMB584,750,000 to RMB601,400,000 by issuing 16,650,000 new Shares to
three investors at an aggregate consideration of RMB299,700,000. The registration of such
increase of registered capital with the Administration for Industry and Commerce was
completed on April 2, 2018.

Save as disclosed above and in this prospectus, there has been no alteration in our share

capital within two years immediately preceding the date of this prospectus.

Immediately after the completion of the Global Offering, our registered capital will be
RMB760,310,000, consisting of 601,400,000 Domestic Shares and 158,910,000 H Shares,
which represent approximately 79% and 21% of our registered capital, respectively (assuming
the Over-allotment Option is not exercised and without regard to the 2018 Convertible Bonds
and the Pre-IPO Options).

C. Changes in the Share Capital of Our Subsidiaries

Our subsidiaries as of June 30, 2018 are set out in the Accountants’ Report, the text of
which is set out in Appendix I to this prospectus. Save as disclosed below and in “Our History
and Development” of this prospectus, there has been no alteration in the share capital of any
of our subsidiaries within the two years immediately preceding the date of this prospectus.

1.

Junshi Biotechnology

As at the date of its establishment on June 29, 2016, the registered capital of Junshi
Biotechnology was RMB50,000,000 and was wholly-owned by our Company. On May 15,
2017, its registered capital was increased from RMB50,000,000 to RMB150,000,000, which
was contributed solely by our Company. On October 10, 2017, its registered capital increased
from RMB150,000,000 to RMB350,000,000, which was contributed solely by our Company.
On November 28, 2018, our Shareholders resolved to increase capital in Junshi Biotechnology
by RMB650,000,000 by way of cash injection and debt for equity swap. As of the Latest
Practicable Date, the registration of such increase of registered capital with the Administration
for Industry and Commerce has not yet been completed.

2.

Jiangsu Union Biopharm

From January 1, 2016 up to July 13, 2018, the registered capital of Jiangsu Union
Biopharm was RMB5,000,000 and it was wholly-owned by our Company. On July 13, 2018,
its registered capital was increased from RMB5,000,000 to RMB35,000,000, which was

– V-3 –

